乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

ASCO

<乌鸦传媒>Trial Results Spark Talk of Curing More Metastatic Cervical Cancers

Adding pembrolizumab to standard care extends overall survival by a year

<乌鸦传媒>P53 Antagonist Shows Early Activity in Advanced Liposarcoma

ASCO roundup: ADC targeting CD46 slows mCRPC, molecule stabilizes effects of "hot spot" mutation

<乌鸦传媒>Intensified Regimen for Metastatic CRC Fails to Improve Outcomes

Combination of modified FOLFOXIRI/panitumumab also caused greater toxicity, study showed

<乌鸦传媒>A Better Way to Irradiate Lethal CNS Metastases?

Randomized trial makes case for proton craniospinal irradiation for leptomeningeal spread

<乌鸦传媒>First-Line Anti-EGFR Extends OS in Left-Sided Colorectal Cancer

"A win for a highly selected group of patients," says ASCO expert

<乌鸦传媒>PARP Inhibitor Picks Up a Win in Frontline Maintenance for Ovarian Cancer

Median PFS more than doubled with rucaparib after response to platinum-based chemotherapy

<乌鸦传媒>Forego Radiotherapy for Women With Low-Risk Luminal A Breast Cancer?

Study shows 5-year local recurrence rate of 2.3% with lumpectomy and endocrine therapy alone

<乌鸦传媒>Targeted Combo Topples Chemo in Pediatric Glioma With BRAF Mutations

ORR quadrupled, median PFS nearly tripled with dabrafenib plus trametinib in low-grade disease

<乌鸦传媒>Radiation Alone May Suffice for Some Nasopharyngeal Cancer

Chemotherapy adds little benefit in intermediate grade lesions

<乌鸦传媒>Novel Agent Lessens Mucositis in Head and Neck Cancers

IV infusion could allow more patients to complete treatment regimen

<乌鸦传媒>Tiragolumab Fails in Extensive-Stage Small Cell Lung Cancer

No change in survival when combined with atezolizumab and chemotherapy

<乌鸦传媒>Liquid Biopsy May Save Colon Cancer Patients From Chemo

Circulating tumor DNA could determine who needs more therapy

<乌鸦传媒>Endocrine Switch Plus Ribociclib Active in Post-CDK4/6 Inhibitor Progression

First randomized support for strategy in progressive metastatic HR+/HER2- breast cancer

<乌鸦传媒>Myeloma Trial Supports 'Personalized Approach' to Upfront Transplant

DETERMINATION confirms benefit in triple-therapy setting, but suggests timing can be tailored

<乌鸦传媒>Complete Responses in 100% of dMMR Rectal Cancer With Neoadjuvant PD-1 Inhibition

Chemo, RT, surgery avoided in short-term follow-up but study population was small

<乌鸦传媒>Trastuzumab Deruxtecan Ushers in New Treatment Era for HER2-Low Breast Cancer

DESTINY-Breast04 extends agent's benefits to historically tough-to-treat disease

<乌鸦传媒>Will High-Dose Ifosfamide Become the Go-To Therapy in Recurrent Ewing Sarcoma?

Data from European rEECur trial "are potentially practice changing," expert says

<乌鸦传媒>Third-Line BTK Inhibitor Combo Doubles PFS in Follicular Lymphoma

Significantly more responses, CRs with zanubrutinib-obinutuzumab versus anti-CD20 drug alone

<乌鸦传媒>Capivasertib-Fulvestrant Combo Ups Survival in ER+/HER2- Metastatic Breast Cancer

But benefit seems to be predominantly in patients with PI3K/AKT/PTEN pathway alterations

<乌鸦传媒>Sacituzumab Govitecan Boosts PFS in Late-Line HR+/HER2- Metastatic Breast Cancer

"This may be something that really changes the lives of these women for the better," expert says

<乌鸦传媒>Immunotherapy Rechallenge in NSCLC Yields Overall Survival Boost

Phase II trial sees "synergistic benefit" with checkpoint blockade and anti-angiogenesis

<乌鸦传媒>IL-15 Agonist Impresses in Non-Muscle Invasive Bladder Cancer

High response rate, 99%-100% cancer-specific survival at 2 years

<乌鸦传媒>Brentuximab Vedotin-Chemo Boosts EFS in High-Risk Pediatric Hodgkin Lymphoma

Combo regimen offers "a new standard for front-line therapy," researcher says

<乌鸦传媒>KRAS Inhibitor Shrinks Tumors in Over 40% of NSCLC Patients

Median survival surpasses 1 year in heavily pretreated population

<乌鸦传媒>Add-On Ibrutinib Boosts PFS in Untreated, Older Mantle-Cell Lymphoma Patients

BTK inhibitor plus chemoimmunotherapy increased progression-free survival by over 2 years

<乌鸦传媒>Survival Bump With EGFR Inhibitor for KRAS Wild-Type Pancreatic Cancer

But generalizability of "notable" Chinese study questioned

<乌鸦传媒>Increased Public Assistance Tied to Better Cancer Survival in Black Patients

Disparity in 5-year OS declined by more than 40% with each 10% boost in public welfare spending

<乌鸦传媒>Cancer Outcome Disparities Not Fully Explained by Race, Socioeconomic Factors

Worse 5-year OS in Hispanic children with high-risk neuroblastoma in adjusted analysis

<乌鸦传媒>Black Patients Often Never Given a Chance to Join Breast Cancer Trials

But survey finds several actionable findings that could boost enrollment

<乌鸦传媒>COVID Increased Use of Telemedicine for Cancer Care, Though Not Equitably

Black, uninsured, non-urban patients less likely to use these services

<乌鸦传媒>Tweaking Maintenance Options in Metastatic CRC

Two studies move the needle, but no major breakthroughs

<乌鸦传媒>Bispecific Antibody Active in NRG1-Positive Pancreatic Cancer

Zenocutuzumab turns in promising results in early-phase trial involving multiple solid tumors

<乌鸦传媒>Promising Early Data for Bladder-Sparing Cancer Treatment

Bladder-intact DFS at 1 year nears 90% for muscle-invasive bladder cancer

<乌鸦传媒>TRK Inhibitor Proves Beneficial in Primary CNS Tumors

One-year OS rate with larotrectinib was 85%

<乌鸦传媒>New Standard for Metastatic Castration-Sensitive Prostate Cancer?

Triplet regimen reduced the risk for radiographic progression or death, but OS data await

<乌鸦传媒>'Important' Advance in Tough-to-Treat Thyroid Cancer

Targeted therapy cabozantinib may represent a new standard in heavily pretreated patients

<乌鸦传媒>More Support for Gene Assay to Guide Breast Cancer Treatment

More nuanced data on treatment de-escalation, extended endocrine therapy

<乌鸦传媒>Another CAR-T Impresses in Follicular Lymphoma

Complete responses in 66% of patients with relapsed or refractory disease

<乌鸦传媒>BPAs Cut Fracture Risk in Metastatic Prostate Cancer

Those receiving enzalutamide with and without radium-223 saw benefits in updated safety analysis

<乌鸦传媒>Acalabrutinib Offers Less Wear and Tear on the Heart in CLL Patients

BTK inhibitor had less cardiotoxicity than ibrutinib, but similar efficacy

2